CSLSTU:CSJ -0.54%83 ROE % is 4.19% as of Dec. 2025, which is 87% below its 10-year median of 33.11. GuruFocus rates STU:CSJ with a GF Score™ of 83/100 and a GF Value™ of €165.40 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,255 Biotechnology companies, CSL ranks better than 80.88% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CSL's annualized net income for the quarter that ended in Dec. 2025 was €685 Mil. CSL's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €16,349 Mil. Therefore, CSL's annualized ROE % for the quarter that ended in Dec. 2025 was 4.19%.
The historical rank and industry rank for CSL's ROE % or its related term are showing as below:
STU:CSJ'
s ROE % Range Over the Past 10 Years
Min: 2.09 Med: 33.11 Max: 47.92
Current: 2.09
During the past 13 years, CSL's highest ROE % was 47.92%. The lowest was 2.09%. And the median was 33.11%.
STU:CSJ's ROE % is ranked better than 80.88% of 1255
companies
in the Biotechnology industry
Industry Median: -38.34
vs STU:CSJ: 2.09
CSL (STU:CSJ) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CSL ROE % Related Terms
CSL ROE % Historical Data
* Premium members only.
The historical data trend for CSL's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's ROE % distribution charts can be found below:
* The bar in red indicates where CSL's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
CSL (STU:CSJ) has a ROE % of 4.19% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CSL and its competitors. This is 87% below median its historical median of 33.11. Over the past decade, CSL's ROE % has ranged from 2.09 to 47.92. According to the industry distribution chart, CSL ranks #240 out of 1255 companies in the Biotechnology industry, placing it in the top 19.1%.
Is CSL's ROE % too high?
CSL's current ROE % of 4.19% is 87% below median its 10-year median of 33.11. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 47.92. Based on the distribution chart, CSL ranks #240 out of 1255 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #240 out of 1255 companies for ROE %. This places CSL in the top 19% of its industry — outperforming the majority of peers. Historically, CSL's own ROE % has ranged from 2.09 to 47.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CSL and its competitors. CSL's current ROE % is 4.19%, which is 87% below median its own 10-year median of 33.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (STU:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €165.40, compared to a current price of €68.23 — trading 58.7% below its estimated fair value. The current ROE % is 4.19%, which is 87% below median its 10-year median of 33.11. CSL's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CSL (STU:CSJ), the current ROE % is 4.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (STU:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €68.23 is trading 58.7% below its estimated GF Value™ of €165.40.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for STU:CSJ:
ROE %: 4.19% (87% below median its 10-year median of 33.11)
GF Value™: €165.40 vs. price of €68.23 (58.7% below fair value)
No single metric tells the full story. See the STU:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
83GF Score
Get the complete analysis for STU:CSJ
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CSJ has been successfully added to your 
